Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. Centessa Pharmaceuticals plc was incorporated in 2020 and is headquartered in Altrincham, United Kingdom with an additional office in Boston, Massachusetts. As of June 24, 2026, Centessa Pharmaceuticals plc operates as a subsidiary of Eli Lilly and Company.
Frequently asked questions
What sector does CENTESSA PHARMACEUTICALS (260) operate in?
CENTESSA PHARMACEUTICALS belongs to the Healthcare sector and operates in the industry.
What is CENTESSA PHARMACEUTICALS (260) current stock price?
As of the latest data, CENTESSA PHARMACEUTICALS stock price is €34.60, with a previous close of €34.60.
What is CENTESSA PHARMACEUTICALS (260) current market capitalization?
CENTESSA PHARMACEUTICALS market cap is approximately 5.35 billion.
What is CENTESSA PHARMACEUTICALS (260) Earnings Per Share (EPS)?
The trailing EPS is -€1.56.
Does CENTESSA PHARMACEUTICALS (260) pay dividends?
No. CENTESSA PHARMACEUTICALS does not pay a dividend.
What is CENTESSA PHARMACEUTICALS (260) beta (volatility) score?
CENTESSA PHARMACEUTICALS has a beta of 1.108, meaning its volatility is roughly in line with the market.
